Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00869167 · ClinicalTrials.gov registry record · Phase 3
Ramelteon for Insomnia Comorbid With Asthma
A Phase 3 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT00869167: Clinical Trial Phase 3 study, sponsored by Northwestern University.
NCT00869167 is a Phase 3 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 2 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00869167, a Phase 3 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
This trial will test the efficacy and safety of ramelteon, a selective melatonin agonist, on patients with insomnia comorbid with asthma.
Primary Outcome
The change in ISI and PSQI from baseline to end of study will be compared between the two groups. PSQI has a score range of 0-21, with lower the number being less sleep disturbances ISI has a score range of 0-28, with lower score meaning less insomnia symptoms
Interventions
- DRUG Ramelteon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Why NCT00869167 stopped before completion
NCT00869167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Ramelteon is the first listed.
NCT00869167 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00869167 about?
NCT00869167 is a clinical study titled "Ramelteon for Insomnia Comorbid With Asthma". This trial will test the efficacy and safety of ramelteon, a selective melatonin agonist, on patients with insomnia comorbid with asthma.
What is the current status of trial NCT00869167?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2008-03. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00869167?
The interventions under investigation include: Ramelteon (DRUG).
Who is sponsoring clinical trial NCT00869167?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00869167's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia